Skip to content

Clinical Evaluation of Two Daily Disposable Toric Soft Contact Lenses Over One Week of Wear

Clinical Evaluation of Two Daily Disposable Toric Soft Contact Lenses Over One Week of Wear

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05291936
Enrollment
78
Registered
2022-03-23
Start date
2022-03-30
Completion date
2022-05-27
Last updated
2023-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular Physiology

Brief summary

This is a bilateral wear, dispensing, randomized, controlled, double-masked, 2-sequence ×2-period crossover study to evaluate ocular physiology following contact lens wear.

Interventions

DEVICEMyDay® Toric Soft Contact Lenses

CONTROL

DEVICEPRECISION1® for Astigmatism Contact Lenses

TEST

Sponsors

Johnson & Johnson Vision Care, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 39 Years
Healthy volunteers
Yes

Inclusion criteria

Potential subjects must satisfy of all the following criteria to be enrolled in the study. The subject must: 1. Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form. 2. Appear able and willing to adhere to the instructions set forth in this clinical protocol. 3. Be between 18 and 39 (inclusive) years of age at the time of screening. 4. By self-report, habitually wear soft contact lenses in both eyes in a daily reusable or daily disposable wear modality (i.e. not extended wear modality). Habitual wear is defined as a minimum of 6 hours of wear per day, for a minimum of 2 days per week during the past month. 5. Possess a wearable pair of spectacles that provide correction for distance vision. Inclusion Criteria at Baseline Evaluation The subject must: 6. Have the spherical component of their vertex-corrected distance refraction must be between -0.875 to -4.625 DS (inclusive) in each eye. 7. Have the magnitude of the cylindrical component of their vertex-corrected distance refraction between 0.625 DC and 1.625 DC in both eyes. 8. Have the cylinder axis of their distance refraction between 165° and 15° (i.e., 180±15°, inclusive) or between 75° and 105° (i.e., 90±15°, inclusive) in each eye. 9. Have best corrected monocular distance visual acuity of 20/30 or better in each eye.

Exclusion criteria

Potential subjects who meet any of the following criteria will be excluded from participating in the study: The subject must not: 1. Be currently pregnant or lactating. 2. Be diabetic. 3. Be currently using any ocular medications or have any ocular infection of any type. 4. By self-report, have any ocular or systemic disease, allergies, infection, or use of medication that might contraindicate or interfere with contact lens wear, or otherwise compromise study endpoints, including infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive disease (e.g., Human Immunodeficiency Virus \[HIV\]), autoimmune disease (e.g. rheumatoid arthritis, Sjögren's syndrome), or history of serious mental illness or seizures. See section 9.1 for additional details regarding excluded systemic medications. 5. Have habitually worn rigid gas permeable (RGP) lenses, orthokeratology lenses, or hybrid lenses (e.g. SynergEyes, SoftPerm) within the past 6 months. 6. Be currently wearing monovision or multifocal contact lenses. 7. Be currently wearing lenses in an extended wear modality. 8. Have a history of strabismus or amblyopia. 9. Be an employee (e.g., Investigator, Coordinator, Technician) or immediate family member of an employee (including partner, child, parent, grandparent, grandchild or sibling of the employee or their spouse) of the clinical site. 10. Have participated in a contact lens or lens care product clinical trial within 7 days prior to study enrollment.

Design outcomes

Primary

MeasureTime frameDescription
Proportion of Eyes With Grade 3 or Higher Slit Lamp FindingsUp to 1-Week Follow-upSlit Lamp Findings (SLF) were assessed using a biomicroscope and was graded using the FDA grading scale (Grade: 0, 1,2, 3 and 4) with grade 0 represents the absence of findings and 1 to 4 representing successively worse findings (i.e. Grade 1 = trace, Grade 2 = Mild, Grade 3 = moderate and Grade 4 = severe). This was performed on each subject eye at every study visit (baseline, unscheduled visits and 1-week follow-up). The data was then dichotomized into two groups. Those with grade 3 or higher and those with grade 2 or lower. The proportion of eyes with SLF with grade 3 or higher was reported.

Countries

United States

Participant flow

Recruitment details

A total of 78 subjects were enrolled in this study. Of those enrolled, 73 subjects were dispensed at least one study lens, while 5 subjects failed to meet all eligibility criteria. Of those dispensed, 69 subjects completed the study while 4 subjects were discontinued.

Participants by arm

ArmCount
Dispensed Subjects
All subjects dispensed a study lens.
73
Total73

Withdrawals & dropouts

PeriodReasonFG000FG001
Period 1Unsatisfactory Visual Response due to Test Article01
Period 1Withdrew Consent during study10
Period 2Adverse Event01
Period 2Unsatisfactory Visual Response due to Test Article10

Baseline characteristics

CharacteristicDispensed Subjects
Age, Continuous28.9 Years
STANDARD_DEVIATION 5.33
Race/Ethnicity, Customized
Asian
3 Participants
Race/Ethnicity, Customized
Black or African American
7 Participants
Race/Ethnicity, Customized
Other
1 Participants
Race/Ethnicity, Customized
White
62 Participants
Region of Enrollment
United States
73 Participants
Sex: Female, Male
Female
48 Participants
Sex: Female, Male
Male
25 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 720 / 72
other
Total, other adverse events
0 / 720 / 72
serious
Total, serious adverse events
0 / 720 / 72

Outcome results

Primary

Proportion of Eyes With Grade 3 or Higher Slit Lamp Findings

Slit Lamp Findings (SLF) were assessed using a biomicroscope and was graded using the FDA grading scale (Grade: 0, 1,2, 3 and 4) with grade 0 represents the absence of findings and 1 to 4 representing successively worse findings (i.e. Grade 1 = trace, Grade 2 = Mild, Grade 3 = moderate and Grade 4 = severe). This was performed on each subject eye at every study visit (baseline, unscheduled visits and 1-week follow-up). The data was then dichotomized into two groups. Those with grade 3 or higher and those with grade 2 or lower. The proportion of eyes with SLF with grade 3 or higher was reported.

Time frame: Up to 1-Week Follow-up

Population: All dispensed subjects regardless of subsequent withdrawal from study or deviation from protocol.

ArmMeasureValue (NUMBER)
Verofilcon AProportion of Eyes With Grade 3 or Higher Slit Lamp Findings0 Proportion of eyes
Stenfilcon AProportion of Eyes With Grade 3 or Higher Slit Lamp Findings0 Proportion of eyes

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026